Zydus Cadila receives final approval from USFDA for Doxazosin Tablets

10 Jul 2017 Evaluate

Zydus Cadila has received the final approval from the USFDA to market Doxazosin Tablets USP, 1 mg, 2 mg, 4 mg, and 8 mg. The drug is a selective alpha blocker used to treat high blood pressure and urinary retention associated with benign prostatic hyperplasia. It has also received the tentative approval from the USFDA to market Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg. The drug is an atypical anti-psychotic used in the treatment of schizophrenia.

Both Doxazosin Tablets and Lurasidone Hydrochloride Tablets will be produced at the group’s formulations manufacturing facility at the Pharma SEZ in Ahmedabad. The group now has more than 120 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.


Zydus Lifesciences Share Price

881.95 -2.90 (-0.33%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×